ArticleFrontiers in immunology2015
Induction of Protective Immune Responses Against Schistosomiasis haematobium in Hamsters and Mice Using Cysteine Peptidase-Based Vaccine.
Article in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Schistosoma japonicum cathepsin L1: A potential target for anti-schistosomiasis strategies.PLoS neglected tropical diseases · 2025Article
- Schistosoma mansoni vaccine candidates identified by unbiased phage display screening in self-cured rhesus macaques.NPJ vaccines · 2024Article
- Increased hepatic interleukin-1, arachidonic acid, and reactive oxygen species mediate the protective potential of peptides shared by gut cysteine peptidases against Schistosoma mansoni infection in mice.PLoS neglected tropical diseases · 2023Article
- Pattern recognition receptor signaling and innate immune responses to schistosome infection.Frontiers in cellular and infection microbiology · 2022Review
- A comprehensive and critical overview of schistosomiasis vaccine candidates.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Review
- Article
- Current status and future prospects of protein vaccine candidates againstParasite epidemiology and control · 2020Review
- Adjuvant-free schistosome cathepsin L3 is an efficacious schistosomiasis vaccine-comment on Huang et al.: Characteristics and function of cathepsin L3 from Schistosoma japonicum.Parasitology research · 2020Article
- Duplex real-time PCR for sexing Schistosoma japonicum cercariae based on W chromosome-specific genes and its applications.PLoS neglected tropical diseases · 2020Article
- T Lymphocyte-Mediated Liver Immunopathology of Schistosomiasis.Frontiers in immunology · 2020Review
- Arachidonic Acid Is a Safe and Efficacious Schistosomicide, and an Endoschistosomicide in Natural and Experimental Infections, and Cysteine Peptidase Vaccinated Hosts.Frontiers in immunology · 2020Review
- Role of T lymphocytes and papain enzymatic activity in the protection induced by the cysteine protease againstJournal of advanced research · 2019Article
- Schistosomiasis: Life Cycle, Diagnosis, and Control.Current therapeutic research, clinical and experimental · 2019Review
- Is arachidonic acid an endoschistosomicide?Journal of advanced research · 2018Article
- iTRAQ-Based Comparative Proteomic Analysis of AdultFrontiers in microbiology · 2018Article
- Immune Mechanisms Involved inFrontiers in immunology · 2018Article
- Physiological functions and pathogenic potential of uric acid: A review.Journal of advanced research · 2017Review
- Protective immune responses against Schistosoma mansoni infection by immunization with functionally active gut-derived cysteine peptidases alone and in combination with glyceraldehyde 3-phosphate dehydrogenase.PLoS neglected tropical diseases · 2017Article
- Development of a schistosomiasis vaccine.Expert review of vaccines · 2016Review
- Excretion/secretion products from Schistosoma mansoni adults, eggs and schistosomula have unique peptidase specificity profiles.Biochimie · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the major lessons we learned from the radiation-attenuated cercariae vaccine studies is that protective immunity against schistosomiasis is dependent on the induction of T helper (Th)1-/Th2-related immune responses. Since most schistosome larval and adult-worm-derived molecules used for vaccination uniformly induce a polarized Th1 response, it was essential to include a type 2 immune response-inducing molecule, such as cysteine peptidases, in the vaccine formula. Here, we demonstrate that a single subcutaneous injection of Syrian hamsters with 200 μg active papain, 1 h before percutaneous exposure to 150 cercariae of Schistosoma haematobium, led to highly significant (P < 0.005) reduction of >50% in worm burden and worm egg counts in intestine. Immunization of hamsters with 20 μg recombinant glyceraldehyde 3-phosphate dehydrogenase (rSG3PDH) and 20 μg 2-cys peroxiredoxin-derived peptide in a multiple antigen peptide construct (PRX MAP) together with papain (20 μg/hamster), as adjuvant led to considerable (64%) protection against challenge S. haematobium infection, similar to the levels reported with irradiated cercariae. Cysteine peptidases-based vaccination was also effective in protecting outbred mice against a percutaneous challenge infection with S. haematobium cercariae. In two experiments, a mixture of Schistosoma mansoni cathepsin B1 (SmCB1) and Fasciola hepatica cathepsin L1 (FhCL1) led to highly significant (P < 0.005) reduction of 70% in challenge S. haematobium worm burden and 60% reduction in liver egg counts. Mice vaccinated with SmCB1/FhCL1/rSG3PDH mixture and challenged with S. haematobium cercariae 3 weeks after the second immunization displayed highly significant (P < 0.005) reduction of 72% in challenge worm burden and no eggs in liver of 8-10 mice/group, as compared to unimmunized mice, associated with production of a mixture of type 1- and type 2-related cytokines and antibody responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.